From SOP revision to understood, not just signed.
The problemA read-and-sign proves a signature, not understanding.
Watch the films
The industry today
Signed by everyone. Understood by whom?
A pharmaceutical plant runs on procedures. Every SOP revision starts a clock: the effective date arrives, and analysts, operators and packers must be trained before they touch the work. In practice that often means a read-and-sign in the LMS, a queue of signatures on Friday and a training matrix that turns green. QA can show who signed. It is much harder to show who understood, and EU GMP expects the effectiveness of training to be assessed.
The same gap runs from the bench to the field. Data integrity fails quietly, on a sticky note or a result written up after lunch. ICH E6(R3) asks clinical teams to rethink how they manage quality. Reps and medical science liaisons must stay on label while a physician presses for more, and pharmacovigilance depends on anyone recognising an adverse event and passing it on in time. In the Gulf, SFDA and Emirates Drug Establishment expectations sit on top, and Arabic-speaking teams need the same clarity as the English SOP.
